Cal Bio/LyphoMed microemulsion delivery
Executive Summary
LyphoMed will license rights to Cal Bio's microemulsion drug delivery technology in the U.S. and Canada with options for rights in other countries. LyphoMed's first use of the system will be for delivery of vitamins to premature infants; clinicals are expected to start late in 1988. LyphoMed has the option to extend the delivery system to other drugs.